@prefix biolink: .
@prefix dcterms: .
@prefix this: .
@prefix sub: .
@prefix np: .
@prefix rdf: .
@prefix nt: .
@prefix xsd: .
@prefix rdfs: .
@prefix orcid: .
@prefix nkg: .
@prefix prov: .
@prefix npx: .
sub:Head {
this: np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubinfo;
a np:Nanopublication .
}
sub:assertion {
biolink:category biolink:Disease .
sub:association rdf:object ;
rdf:predicate biolink:treats;
rdf:subject ;
a rdf:Statement;
rdfs:label "Currently, no medication has been approved for use in the USA for cognition in DLB but there is class I evidence suggesting that donepezil and rivastigmine improve cognition and global function ]";
biolink:association_type biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
biolink:has_population_context sub:cohort;
biolink:provided_by ;
biolink:publications ;
biolink:relation nkg:OffLabelIndication .
sub:cohort rdfs:label "Elderly";
biolink:category biolink:Cohort .
biolink:category biolink:Drug .
}
sub:provenance {
sub:assertion prov:wasAttributedTo orcid:0000-0002-7641-6446 .
}
sub:pubinfo {
sub:sig npx:hasAlgorithm "RSA";
npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCamPJb4SzqpLXn//XJ5dlVfzz6QI+RPmiJTLXF/by2JR7sHMKRsCQDFsYMlq8zGHghOIkjRP9dpLZUtZzUcHt3MXiFKEPo8eGzUe9p+JXKFC8xxkJr94z2vq6IdMf71Iu1GH8SeDAKt/DgYO4zNaw8VuXvxnZRewKZSA+u8zWPVwIDAQAB";
npx:hasSignature "Z4WLA5yeJW2Qsh3hieLNtUsfUjPb5w4vxCYlGsSoB6knGBZOhj3OS8h5LExSx53FAgZTFNxtJpRAuZ52K30isvShvRNsQbnTm/xC0RNecpnLc5Nk/6MHCDDnpAVSw3doCixDuNX/5xQHT/SOmiqwW5qmXz5gVxyrTAqWeXOOtY4=";
npx:hasSignatureTarget this: .
this: dcterms:created "2021-05-19T12:11:51.185+02:00"^^xsd:dateTime;
dcterms:creator orcid:0000-0002-7641-6446;
nt:wasCreatedFromProvenanceTemplate ;
nt:wasCreatedFromPubinfoTemplate ;
nt:wasCreatedFromTemplate .
}